Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 11/20 | 0.48 |
| ▸ | CNR1 | P21554 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | PLK1 | P53350 | 2/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4234228 | 0.84 | CNR2 (0.50) | CNR2CNR1KDM4ECREBBPPLK1 | |
| SCHEMBL4240678 | 0.77 | ESRRG (0.50) | ALDH1A1KDM4EHPGDHSD17B10MAPT | |
| SCHEMBL4238844 | 0.75 | SLC22A12 (0.47) | CNR2CNR1ALDH1A1KDM4EHPGD | |
| SCHEMBL9340446 | 0.75 | IDO1 (0.51) | CNR2CNR1PLK1ENPP2 | |
| SCHEMBL5450086 | 0.72 | CNR2 (0.62) | CNR2CNR1ALDH1A1CREBBPPLK1 | |
| SCHEMBL10086144 | 0.71 | CNR2 (0.49) | CNR2CNR1ALDH1A1KDM4EHPGD | |
| SCHEMBL4238803 | 0.71 | ESRRG (0.48) | ALDH1A1KDM4EHPGDHSD17B10MAPT | |
| SCHEMBL9340471 | 0.70 | CNR2 (0.70) | CNR2CNR1ALDH1A1KDM4EMAPT | |
| SCHEMBL548607 | 0.70 | CNR2 (0.70) | CNR2CNR1ALDH1A1KDM4EMAPT | |
| Hydrochloric Acid SCHEMBL2035939 | 0.69 | CNR2 (0.68) | CNR2CNR1ALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | CNR2 24/4885CNR1 32/4885ALDH1A1 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.